Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 18/20 | 0.66 |
| ▸ | CYP11B2 | P19099 | 18/20 | 0.66 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6599640 | 0.85 | CYP11B1 (0.72) | CYP11B1CYP11B2CYP19A1HTTSMN1; SMN2 | |
| SCHEMBL3820773 | 0.84 | CYP11B1 (0.76) | CYP11B1CYP11B2CYP19A1LMNAHTT | |
| SCHEMBL6599385 | 0.84 | CYP11B1 (0.48) | CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL6599480 | 0.83 | CYP11B1 (0.73) | CYP11B1CYP11B2CYP19A1IDO1 | |
| Hydrochloric Acid SCHEMBL6927027 | 0.83 | CYP11B1 (0.49) | CYP11B1CYP11B2CYP19A1TP53MAPT | |
| SCHEMBL3079356 | 0.83 | CYP11B1 (0.71) | CYP11B1CYP11B2HTTIDO1 | |
| SCHEMBL6929673 | 0.83 | CYP11B1 (0.75) | CYP11B1CYP11B2IDO1 | |
| SCHEMBL3822319 | 0.82 | CYP11B1 (0.52) | CYP11B1CYP11B2CYP19A1TP53MAPT | |
| SCHEMBL6926694 | 0.81 | CYP11B1 (0.52) | CYP11B1CYP11B2TP53MAPTLMNA | |
| SCHEMBL3630524 | 0.80 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1188407-C | Imidazole derivatives with inhabiting activity to transterasa and preparing method thereof | LG CHEMICAL LTD (KR) | 2005-02-09 | — | — | CN | disclosed |
| EP-1045846-B1 | IMIDAZOLE DERIVATIVES HAVING AN INHIBITORY ACTIVITY FOR FARNESYL TRANSFERASE AND PROCESS FOR PREPARATION THEREOF | LG CHEMICAL LTD (KR) | 2003-05-02 | — | — | EP | disclosed |
| US-6518429-B2 | Anticancer agents, treating restenosis, atherosclerosis and hepatitis virus | LG CHEMICAL, LTD. (KR) | 2003-02-11 | — | — | US | disclosed |
| US-6472526-B1 | SHOWS AN INHIBITORY ACTIVITY AGAINST FARNESYL TRANSFERASE OR PHARMACEUTICALLY ACCEPTABLE SALTS OR ISOMERS THEREOF, IN PHARMACEUTICAL COMPOSITION AND INTERMEDIATES | LG CHEMICAL LTD. (KR) | 2002-10-29 | — | — | US | disclosed |
| US-20020137769-A1 | Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof | LG CHEMICAL LTD. | 2002-09-26 | — | — | US | disclosed |
| US-6268363-B1 | ANTITUMOR | LG CHEMICAL LTD. (KR) | 2001-07-31 | — | — | US | disclosed |
| CN-1279680-A | Imidazole derivatives having farnesyl transferase inhibitory activity and process for producing the same | LG CHEMICAL LTD (KR) | 2001-01-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137769-A1 | Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof | FNTA, FNTB, FDPS | CYP11B1 74/4885CYP11B2 110/4885CYP19A1 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.